Molecular Partners AG (MOLN)
5.38
-0.10 (-1.82%)
At close: Jan 14, 2025, 3:58 PM
5.36
-0.37%
After-hours Jan 14, 2025, 03:59 PM EST
undefined% (undefined)
| Bid | 5.42 |
| Market Cap | 198.32M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.06 |
| PE Ratio (ttm) | -2.61 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 6.19 |
| Volume | 5,938 |
| Avg. Volume (20D) | 24,862 |
| Open | 5.49 |
| Previous Close | 5.48 |
| Day's Range | 5.38 - 5.50 |
| 52-Week Range | 3.32 - 12.70 |
| Beta | undefined |
About MOLN
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for th...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 16, 2021
Employees 167
Stock Exchange NASDAQ
Ticker Symbol MOLN
Analyst Forecast
According to 1 analyst ratings, the average rating for MOLN stock is "Hold." The 12-month stock price forecast is $4.5, which is a decrease of -16.36% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
2 months ago ·
Source
+14.18%
Molecular Partners shares are trading higher after...
Unlock content with
Pro Subscription
7 months ago ·
Source
+13.78%
Molecular Partners shares are trading higher after the comapny announced preclinical proof-of-concept data from MP0621.
